Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Interim Ana... von Wang, G.P, Reeves, J.D, Terrault, N, Lim, J.K, Morelli, G, Kuo, A, Levitsky, J, Sherman, K, Frazier, L.M, Ramani, A, Peter, J, Akuskevich, L, Fried, M.W, Nelson, D.R

Volltext

O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience von Reddy, R, Lim, J.K, Kuo, A, Di Bisceglie, A.M, Vargas, H.E, Galati, J.S, Morelli, G, Everson, G.T, Kwo, P.Y, Brown, R.S, Sulkowski, M.S, Stewart, T.G, Akuskevich, L, Vainorius, M, Peter, J.A, Nelson, D.R, Fried, M.W, Manns, M.P

Volltext

PS102 - Prevalence and Impact of Baseline Resistance-Associated Variants on the Efficacy of Ledipasvir/Sofosbuvir or Simeprevir/Sofosbuvir against GT1 HCV Infection: Hcv-Target Int... von Wang, G.P., Reeves, J.D., Terrault, N., Lim, J.K., Morelli, G., Kuo, A., Levitsky, J., Sherman, K., Frazier, L.M., Ramani, A., Peter, J., Akuskevich, L., Fried, M.W., Nelson, D.R.

Volltext